This technology was applied to target BRD9, and the developed PROTACs dBRD9 [102] and VZ185 [103] (Fig. 4A) were much more effective in treating SMARCB1-mutant cancers than their parent inhibitor BI-7273. The gene discussed is BRD9; the disease is cancer.